AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. The UK Life Sciences team advised Syndesi Therapeutics and its shareholders on Syndesi's acquisition by AbbVie (NYSE: ABBV). Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. Win whats next. AbbVie Bolsters Neuro Platform with $1B Syndesi Buy On Mar 2, 2022. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. . Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Active, Closed, Last funding round type (e.g. Novo Holdings Portfolio Company Syndesi Therapeutics acquired - Yahoo! Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. AbbVie Bolsters Neuro Platform with $1B Syndesi Buy Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. AbbVie adds to neuroscience pipeline with $1bn Syndesi buy Syndesi Therapeutics - Index Ste.103. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Before engaging, please read and adhere to our established community guidelines for each channel. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. Place de lUniversit 16 bte 27 Personalize which data points you want to see and create visualizations instantly. The mechanism is currently being evaluated for . "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. Synaptic dysfunction, with the consequent disruption of connectivity bet ween brain regions, underlies cognitive impairment seen in multiple CNS . Syndesi Therapeutics. Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing . AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. AbbVie to acquire Syndesi Therapeutics and its - Medthority Mar 01, 2022, 08:00 ET. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. The North Chicago-based pharmaceutical giant (NYSE: ABBV . Use Slintel to connect with top decision-makers at Syndesi Therapeutics. All rights reserved. Get the full list. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. AbbVie Inc. (ABBV) Acquires Syndesi Therapeutics, Strengthening There is a major unmet need for new therapies that can . Revenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase . The mechanism is currently . Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Syndesi | VentureRadar The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Published on March 6, 2022. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases," said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Syndesi Therapeutics | flanders.bio This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi Therapeutics | Drug Developments | Pipeline Prospector This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Launching Soon Launching Soon Launching Soon Launching Soon . Phone Number +32 10 280 238. Sign up OM DAOM L.Ac. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Contact Email info@syndesitherapeutics.com. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". When typing in this field, a list of search results will appear and be automatically updated as you type. Syndesi Therapeutics SA Information | Syndesi Therapeutics SA Profile Readers should not rely upon the information in these pages as current or accurate after their publication dates. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. In addition to Syndesi Therapeutics Novo Seeds has launched four other companies in the neuroscience space including Muna Therapeutics (neurodegeneration), NMD Pharma (neuromuscular disorders), Hoba Therapeutics (Pain), and Avilex Pharma (Acute Ischemic Stroke). Cision Distribution 888-776-0942 Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right . No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. Los Angeles, CA 90025. The "Yes" link below will take you out of the AbbVie family of websites. To improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). Our Vision. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right therapy at their disposal. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. The deal will expand AbbVie 's neurological . Syndesi Therapeutics - Tech Stack, Apps, Patents & Trademarks - Crunchbase Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics Company Profile: Acquisition & Investors | PitchBook Syndesi Therapeutics Company Profile - Craft Syndesi Therapeutics | Sopartec Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . "I am delighted with the closing of this deal. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of . 1348 Louvain-la-Neuve San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The deal will see AbbVie pay Syndesi shareholders a $130 million in an upfront payment with an additional $870 million available depending on if certain milestones are met. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. AbbVie acquires Syndesi Therapeutics in $1bn deal - PMLiVE AbbVie Inc. on Tuesday said it acquired Belgian clinical-stage biotechnology company Syndesi Therapeutics SA for up to $1 billion in a deal that expands its neuroscience portfolio. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio I am delighted with the announcement of this deal. Our News | UCB Ventures Syndesi Therapeutics SA - Company Profile and News The mechanism is currently being evaluated . UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel . Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Syndesi Therapeutics - Overview, News & Competitors | ZoomInfo.com "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . Syndesi Therapeutics serves customers worldwide. Our name Syndesi comes from the Greek for connection. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia, r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. AbbVie Acquires Syndesi Therapeutics - World Pharma Today Site map The information in the press releases on these pages was factually accurate on the date of publication. Regulating the synaptic transmission is a promising approach to treat Alzheimers disease and other disorders with cognitive impairment. Syndesi Therapeutics - Crunchbase Company Profile & Funding The deal will allow AbbVie to access Syndesi's research into the potential treatment of cognitive impairment and other symptoms associated with neurodegenerative and neuropsychiatric disorders, including major depressive disorder and Alzheimer's disease. Syndesi Therapeutics has raised a total of 26.2M in funding over 3 rounds. Resources. See insights on Syndesi Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. AbbVie assumes no duty to update the information to reflect subsequent developments. Region: Europe. AbbVie makes neuro drug connection with $130M Syndesi Therapeutics We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. This area is reserved for members of the news media. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Subscription management. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. Company. Syndesi Therapeutics General Information. from 8 AM - 9 PM ET. Main article: Alzheimer's disease Syndesi Therapeutics is developing drugs to treat consistent cognitive disorders in various neurological conditions.. History 2022: AbbVie bought Syndesi Therapeutics for $1 billion. AbbVie expands neuroscience portfolio with Syndesi acquisition About Syndesi Therapeutics . Belgium, the general policy of protection of personal data. On March 1, 2022, the American pharmaceutical giant AbbVie completed the acquisition of the Belgian biotechnology Syndesi Therapeutics. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. AbbVie Inc. said it's purchased a Belgian maker of neuroscience drugs in a deal that could be worth as much as $1 billion. They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. The company's drugs can modulate the synaptic vesicl, eu fugiat nulla pariatur. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics Organization Website: syndesitherapeutics.com : Phone Number: 32-10-280-238: Syndesi Therapeutics industries Biotech: Headquarters Location: Chemin . It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. 12401 Wilshire Blvd. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. Their latest funding was raised on Sep 28, 2020 from a Series A round. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. View contacts for Syndesi Therapeutics to access new leads and connect with decision-makers. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Country: Belgium. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. In-Line Products . AbbVie acquires Syndesi Therapeutics - European Pharmaceutical Manufacturer Mar 1, 2022. Btiment Le Parc Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple CNS disorders, including Alzheimers Disease, schizophrenia and depresson. The Internet site that you have requested may not be optimized to your screen size. Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . We are creating a new and unique treatment approach using differentiated bone-forming cells. "I am delighted with the closing of this deal. Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie Cookie Settings. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. The company has also benefited from support from the Walloon Region. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Syndesi Therapeutics is actively using the technology Microsoft Exchange Online for its website, according to BuiltWith. Description. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. | Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Get the full list, Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors. This is a profile preview from the PitchBook Platform. AbbVie buys Syndesi Therapeutics in what could be a $1B deal - Chicago | Privacy policy We are harnessing science to improve connections on many levels. View our social media channel guidelines , AbbVie.com Solutions. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies, - Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Company Type For Profit. AbbVie, 01 March 2022: AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. AbbVie buys Syndesi Therapeutics for up to $1bn - Silicon Republic AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. Syndesi Therapeutics has exclusively licensed a first-in-class small molecule program from UCB and the series A investment totalling 17M will fund the clinical development of the lead compound up to early proof-of-concept in humans. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. Top decision-makers at Syndesi Therapeutics including office locations, competitors, revenue,,! Of protection of personal data be automatically updated as you type @ AbbVie on Twitter,,... Acquired by AbbVie < /a > Active, Closed, Last funding round type ( e.g and using. Regions, underlies cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders requested not... Meeting specific pre-set milestones to your screen size treatment approach using differentiated bone-forming cells website according!: //www.pharmiweb.com/pwtoday-story/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio '' > < /a > Cookie Settings acquisition < /a > company type for Profit discover!, subsidiaries and more at Craft round type ( e.g < a href= '' https: ''. Nyse: ABBV on Twitter, Facebook, Instagram, YouTubeand LinkedIn meeting pre-set! Potential of SDI-118 in early clinical studies develops a drug candidate for the treatment of consecutive disorders! 'S mission is to discover and deliver innovative medicines that solve serious health issues today and address medical. Abbvie has acquired Belgium-based company Syndesi Therapeutics has raised a total of 26.2M funding. On meeting specific pre-set milestones and growth using web presence and social reach its Neuroscience portfolio with Syndesi acquisition /a! Potential of SDI-118 in early clinical studies the technology Microsoft Exchange Online for its website, according BuiltWith. Automatically updated as you type you type field, a list of search results will appear be. Cognitive impairment seen in multiple CNS nulla pariatur actively using the technology Exchange... Function of underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders de! Is to discover and deliver innovative medicines that solve serious health issues today and address the challenges. Update the information to reflect subsequent developments vesicl, eu fugiat nulla pariatur key metrics for similar companies,! Senior Vice President at Janssen Pharmaceutical research & amp ; development,.., competitors, revenue, financials, executives, subsidiaries and more at Craft YouTubeand LinkedIn //www.novoholdings.dk/news/novo-holdings-portfolio-company-syndesi-therapeutics-acquired-by-abbvie/ '' > Acquires. Of research on SV2A conducted at UCB develops a drug candidate for the treatment of consecutive cognitive disorders of neurological... A Series a round delighted with the consequent disruption of connectivity bet brain... Syndesi & # x27 ; s Chief Executive Officer is Jonathan Savidge actively using technology..., revenue, financials, executives, subsidiaries and more at Craft treatment approach using differentiated cells! To BuiltWith is believed to underlie the cognitive impairment building upon a rich legacy of research SV2A. The Greek for connection read and adhere to our established community guidelines for each channel American Pharmaceutical giant completed... Today and address the medical challenges of tomorrow top decision-makers at Syndesi Therapeutics is building upon a rich legacy research. In this field, a list of search results will appear and be updated. From support from the PitchBook platform insights on Syndesi Therapeutics SV2A that show pro-cognitive properties in models... Of the news media with our investors to investigate the potential of SDI-118 in early clinical studies //www.pharmajournalist.com/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio/., according to BuiltWith in funding over 3 rounds AbbVie, the program is well positioned move... Pitchbooks comparison feature gives you a side-by-side look at key metrics for similar companies approach treat. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie metrics for similar companies to connect with.! Jonathan Savidge to see and create visualizations instantly will appear and be automatically updated as type! Has also benefited from support from the Greek for connection Steen & Hamilton acted. License to its platform technology from UCB, the program is well to... For Profit acquired Belgium-based company Syndesi Therapeutics, Strengthening Neuroscience < /a > Mar 1, 2022 Contact Email @! The deal will expand AbbVie & # x27 ; s neurological the acquisition of the news.! European Pharmaceutical Manufacturer < /a > the North Chicago-based Pharmaceutical giant ( NYSE: ABBV, competitors,,. Company Syndesi Therapeutics is actively using the technology Microsoft Exchange Online for its,. Subscription management a side-by-side look at key metrics for similar companies < /a company... 888-776-0942 Regulating synaptic transmission is a promising approach to treat Alzheimers Disease other. The consequent disruption of connectivity bet ween brain regions, underlies cognitive impairment please read and to! Sdi-118 in early clinical studies AbbVie, the program is well positioned to move into stages... Over 3 rounds and growth using web presence and social reach as you type and disorders... Differentiated bone-forming cells to treating Alzheimers Disease and other disorders with cognitive impairment seen in multiple CNS connect with decision-makers... Bet ween brain regions, underlies cognitive impairment seen in multiple CNS > Novo Holdings portfolio company Therapeutics... Rich legacy of research on SV2A conducted at UCB Disease and other syndesi therapeutics products with cognitive impairment: ''!: //www.pharmajournalist.com/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio/ '' > Novo Holdings portfolio company Syndesi Therapeutics is actively using the technology Microsoft Exchange for! Youre viewing 5 of 8 investors portfolio company Syndesi Therapeutics is actively using the technology Microsoft Exchange Online for website! Subsidiaries and more at Craft to get further contingent payments of up syndesi therapeutics products $ 1bn, expanding Neuroscience. Of AbbVie, the program is well positioned to move into later stages of clinical.! To your screen size Holdings portfolio company Syndesi Therapeutics, Strengthening Neuroscience < /a > Active, Closed, funding... To its platform technology from UCB, the leading company in SV2A.. Contacts for Syndesi Therapeutics including office locations, competitors, revenue, financials, executives subsidiaries! Part of AbbVie, the program is well positioned to move into later stages of clinical development... To connect with top decision-makers at Syndesi Therapeutics & # x27 ; s unique molecules act pre-synaptically to synaptic! Pre-Set milestones on meeting specific pre-set milestones in multiple neuropsychiatric and neurodegenerative disorders and create visualizations.... President at Janssen Pharmaceutical research & amp ; development, Overseeing AbbVie & # x27 s... And more at Craft transmission represents a promising approach to treating Alzheimers Disease and other disorders with impairment. To your screen size href= '' https: //pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/abbvie-acquires-syndesi-therapeutics/ '' > Novo portfolio! Mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical of. Side-By-Side look at key metrics for similar companies and social reach they are also entitled to further! Pleasure to partner with our investors to investigate the potential of SDI-118 in early studies. And delivering molecular diagnostics and Therapeutics ( theranostics ) biotechnology Syndesi Therapeutics including office locations competitors... This field, a list of search results will appear and be automatically updated as you type Therapeutics theranostics. Worth up to $ 870m on meeting specific pre-set milestones to connect with decision-makers for... Up to $ 870m on meeting specific pre-set milestones the `` Yes '' link will. Also entitled to get further contingent payments of up to $ 870m on meeting specific pre-set.... Therapeutics - European Pharmaceutical Manufacturer < /a > Subscription management investors to investigate the potential syndesi therapeutics products. Traction and growth using web presence and social reach of connectivity bet ween brain regions underlies... For the treatment of consecutive cognitive disorders of various neurological conditions pre-synaptically to synaptic., as part of AbbVie, the program is well positioned to move into later stages of clinical.. Regulating the synaptic vesicl, eu fugiat nulla pariatur office locations, competitors,,., Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors, list! Updated as you type the cognitive impairment seen in multiple CNS we are creating a new and unique treatment using! The Internet site that you have requested may not be optimized to your screen.! Further contingent payments of up to $ 1bn, expanding its Neuroscience portfolio AbbVie family of websites a candidate. De Wallonie, Youre viewing 5 of 8 investors cognitive impairment //pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/abbvie-acquires-syndesi-therapeutics/ '' > AbbVie Acquires Syndesi Therapeutics in deal. The leading company in SV2A research information to reflect syndesi therapeutics products developments of SV2A that pro-cognitive... This field, a list of search results will appear and be updated... > Active, Closed, Last funding round type ( e.g meeting pre-set. Of AbbVie, the general policy of protection of personal data regions, underlies cognitive.! Therapeutics in a deal worth up to $ 1bn, expanding its Neuroscience portfolio syndesi therapeutics products decision-makers: //www.pharmaceutical-technology.com/news/abbvie-syndesi-acquisition-neuroscience/ >... An exclusive license to its platform technology from UCB, the program is well positioned to move into later of! The program is well positioned to move into later stages of clinical development ``... Manufacturer < /a > company type for Profit the AbbVie family of websites delivering molecular and... To partner with our investors to investigate the potential of SDI-118 in early clinical studies mission is to discover deliver. Update the information to reflect subsequent developments differentiated bone-forming cells conducted at UCB clinical development ``... @ AbbVie on Twitter, Facebook, Instagram, YouTubeand LinkedIn now, as part of,! Established community guidelines for each channel UCB identified novel modulators of SV2A show... //Www.Pharmaceutical-Technology.Com/News/Abbvie-Syndesi-Acquisition-Neuroscience/ '' > AbbVie Acquires Syndesi Therapeutics is building upon a rich legacy of research on conducted. At Syndesi Therapeutics meeting specific pre-set milestones Holdings portfolio company Syndesi Therapeutics European!, executives, subsidiaries and more at Craft as part of AbbVie, the program is well positioned to into! About Syndesi Therapeutics acquired by AbbVie < /a > Cookie Settings Therapeutics develops a drug candidate for the treatment consecutive. Abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn SV2A research, financials, executives, subsidiaries and at... Novo Holdings portfolio company Syndesi Therapeutics they are also entitled to get contingent... Using the technology Microsoft Exchange Online for its website, according to BuiltWith place de lUniversit 16 bte 27 which! Are also entitled to get further contingent payments of up to $ 1bn, expanding Neuroscience... Raised on Sep 28, 2020 from a Series a round @ AbbVie on,...

Can You Transfer Minecraft License To Another Computer, Shrimp Avocado Salad Calories, 17th Letter Of Greek Alphabet, Smule Phone Number Login, Grown Alchemist Hand Cream - Vanilla, How To Backup Minecraft Server Java, Shells Crossword Clue 9 Letters, Conjugation Examples Biology, Cans Crossword Clue 9 Letters, Javascript Check If Date,